Unencrypted login | home

Program Information

JACK FOWLER JUNIOR INVESTIGATOR COMPETITION WINNER: Between Somatic Mutations and PET-Based Radiomic Features in Non-Small Cell Lung Cancer


S Yip

S Yip1*, J Kim2 , T Coroller1 , E Rios Velazquez1 , C Parmar1 , R Mak1 , H Aerts1 , (1) Brigham and Women's Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, (2) Brigham and Women's Hospital, Boston Children's Hospital and Harvard Medical School, Boston, MA,

Presentations

MO-DE-207B-1 (Monday, August 1, 2016) 1:45 PM - 3:45 PM Room: 207B


Purpose: Although PET-based radiomic features have been proposed to quantify tumor heterogeneity and shown promise in outcome prediction, little is known about their relationship with tumor genetics. This study assessed the association of [¹⁸F]fluorodeoxyglucose (FDG)-PET-based radiomic features with non-small cell lung cancer (NSCLC) mutations.

Methods: 348 NSCLC patients underwent FDG-PET/CT scans before treatment and were tested for genetic mutations. 13% (44/348) and 28% (96/348) patients were found to harbor EGFR (EGFR+) and KRAS (KRAS+) mutations, respectively. We evaluated nineteen PET-based radiomic features quantifying phenotypic traits, and compared them with conventional PET features (metabolic tumor volume (MTV) and maximum-SUV). The association between the feature values and mutation status was evaluated using the Wilcoxcon-rank-sum-test. The ability of each measure to predict mutations was assessed by the area under the receiver operating curve (AUC). Noether’s test was used to determine if the AUCs were significantly from random (AUC=0.50). All p-values were corrected for multiple testing by controlling the false discovery rate (FDRWilcoxon and FDRNoether) of 10%.

Results: Eight radiomic features, MTV, and maximum-SUV, were significantly associated with the EGFR mutation (FDRWilcoxon=0.01–0.10). However, KRAS+ demonstrated no significantly distinctive imaging features compared to KRAS– (FDRWilcoxon≥0.92). EGFR+ and EGFR– were significantly discriminated by conventional PET features (AUC=0.61, FDRNoether=0.04 for MTV and AUC=0.64, FDRNoether=0.01 for maximum-SUV). Eight radiomic features were significantly predictive for EGFR+ compared to EGFR– (AUC=0.59–0.67, FDRNoether=0.0032–0.09). Normalized-inverse-difference-moment outperformed all features in predicting EGFR mutation (AUC=0.67, FDRNoether=0.0032). Moreover, only the radiomic feature normalized-inverse-difference-moment could significantly predict KRAS+ from EGFR+ (AUC=0.65, FDRNoether=0.05). All measures failed to predict KRAS+ from KRAS– (AUC=0.50–0.54, FDRNoether≥0.92).

Conclusion:PET imaging features were strongly associated with EGFR mutations in NSCLC. Radiomic features have great potential in predicting EGFR mutations. Our study may help develop a noninvasive imaging biomarker for EGFR mutation.

Funding Support, Disclosures, and Conflict of Interest: R.M. has consulting interests with Amgen


Contact Email: